Lp-PLA2 is a blood marker linked to inflammation inside artery walls, especially inflammation tied to oxidized LDL particles and atherosclerotic plaque. Unlike broad inflammation tests that can rise with infections, injuries, autoimmune flares, or many other conditions, Lp-PLA2 is often discussed as a more artery-focused signal. A high result does not diagnose a heart attack, stroke, or blocked artery by itself, but it can add information when a clinician is estimating cardiovascular risk, especially in people with borderline or mixed results from standard cholesterol testing.
The test is most useful when it is interpreted alongside LDL cholesterol, ApoB, blood pressure, diabetes status, smoking history, kidney function, family history, and imaging when needed. It is less useful as a stand-alone number. A high Lp-PLA2 result usually points toward a need to look harder at plaque-related risk and to strengthen proven prevention steps.
- Lp-PLA2 measures artery-related inflammatory enzyme activity, most often reported as activity in nmol/min/mL or, less commonly, mass in ng/mL.
- High Lp-PLA2 is linked to atherosclerotic plaque inflammation, especially when LDL, ApoB, non-HDL cholesterol, or other risk factors are also high.
- Many U.S. lab reports use <225 nmol/min/mL as reduced-risk activity and ≥225 nmol/min/mL as increased-risk activity, but reference ranges vary by method.
- Fasting is usually not required for Lp-PLA2 activity testing, though it may be drawn with a fasting lipid panel if other tests need fasting.
- A high result is not an emergency result by itself, but chest pain, stroke symptoms, severe shortness of breath, or sudden weakness need urgent care regardless of the Lp-PLA2 number.
- Lowering cardiovascular risk matters more than chasing the marker alone, because statins and broader risk reduction can lower Lp-PLA2 while also reducing proven heart and stroke risk.
Table of Contents
- What the Lp-PLA2 Test Measures
- Why Lp-PLA2 Rises in Artery Disease
- Lp-PLA2 Ranges and How to Read Results
- High Lp-PLA2, Stroke Risk, and Heart Risk
- Who May Benefit From Lp-PLA2 Testing
- How High Lp-PLA2 Is Usually Addressed
- Follow-Up Tests, Common Mistakes, and Urgent Symptoms
What the Lp-PLA2 Test Measures
The Lp-PLA2 test measures an enzyme involved in lipid oxidation and artery-wall inflammation. Lp-PLA2 stands for lipoprotein-associated phospholipase A2. It is also called platelet-activating factor acetylhydrolase, and it is encoded by the PLA2G7 gene.
In the bloodstream, Lp-PLA2 travels mostly attached to lipoproteins. Most circulating Lp-PLA2 is carried on LDL particles, with a smaller amount carried on HDL particles. This is why the test often belongs in the same conversation as LDL cholesterol, ApoB, LDL particle number, and other atherogenic lipoprotein markers.
Lp-PLA2 is produced by inflammatory cells, especially macrophages. Macrophages are immune cells that enter artery walls and help form atherosclerotic plaque. When LDL particles become oxidized inside the artery wall, Lp-PLA2 can break down oxidized phospholipids. That reaction produces inflammatory molecules, including lysophosphatidylcholine and oxidized fatty acids, which can irritate the artery lining and attract more immune cells.
The result is not a direct picture of one plaque. It is a blood-based signal that may reflect a person’s tendency toward vascular inflammation. A standard lipid panel shows the amount of cholesterol carried in major lipoprotein classes. Lp-PLA2 adds a different type of information: how much of a plaque-related inflammatory enzyme is present or active.
Lp-PLA2 activity versus Lp-PLA2 mass
Lp-PLA2 can be measured in two main ways.
Lp-PLA2 activity measures how active the enzyme is. It is commonly reported in nmol/min/mL. Activity testing is widely used in current commercial testing because it reflects enzyme function rather than only the amount of enzyme protein.
Lp-PLA2 mass measures the amount of enzyme protein. It is commonly reported in ng/mL. Older studies and older PLAC test discussions often used mass cutoffs, so older articles may give ng/mL values that do not match an activity report.
These two results are related, but they are not interchangeable. A result of 225 nmol/min/mL on an activity test is not the same thing as 225 ng/mL on a mass test. When tracking Lp-PLA2 over time, use the same lab method whenever possible.
What the test does not measure
Lp-PLA2 does not measure whether a person is having a heart attack. Troponin is the main blood test used when doctors are checking for heart muscle injury. Lp-PLA2 also does not diagnose an active stroke, a blood clot, or a specific blocked artery.
It also does not replace blood pressure measurement, diabetes testing, kidney function testing, or cholesterol testing. A high result should be treated as one piece of a larger risk picture, not as a final answer.
Why Lp-PLA2 Rises in Artery Disease
Lp-PLA2 tends to rise when lipid oxidation, LDL particle burden, and artery-wall inflammation are more active. The enzyme sits at the intersection of cholesterol transport and immune-cell activity, which makes it different from general inflammation markers.
Atherosclerosis begins when cholesterol-rich particles enter the artery wall. LDL particles, remnant particles, and lipoprotein(a) can become trapped in the inner artery lining. Over time, some of these particles become oxidized. The immune system responds by sending macrophages into the area. Those macrophages take up oxidized lipids, become foam cells, and release inflammatory signals.
Lp-PLA2 is part of that environment. It is found in higher amounts in advanced atherosclerotic lesions than in early lesions. It can generate pro-inflammatory lipid products from oxidized LDL, which may promote endothelial dysfunction, plaque growth, and plaque instability.
This does not mean Lp-PLA2 is “bad” in every biological setting. The enzyme can also break down platelet-activating factor, a molecule involved in inflammation and clotting signals. Its effect depends partly on where it is, what particle carries it, and what substrate it acts on. In routine cardiovascular risk testing, the concern is mainly LDL-associated Lp-PLA2 activity in the setting of atherosclerosis.
Several conditions and patterns can appear with higher Lp-PLA2:
- High LDL cholesterol or high non-HDL cholesterol
- High ApoB or high LDL particle number
- Small dense LDL patterns
- Insulin resistance and metabolic syndrome
- Type 2 diabetes
- Obesity, especially with visceral fat
- Smoking
- Chronic kidney disease
- Established coronary artery disease or carotid plaque
- Prior ischemic stroke or transient ischemic attack
- Older age and long-term exposure to atherogenic particles
Lp-PLA2 is often compared with high-sensitivity C-reactive protein, or hs-CRP. The hs-CRP test measures broader systemic inflammation. It can rise after infection, injury, arthritis flares, intense exercise, and many other triggers. Lp-PLA2 is generally considered more vascular-specific, but that does not make it perfect or automatically more important.
Lp-PLA2 Ranges and How to Read Results
Lp-PLA2 results must be interpreted using the reference range printed on the lab report. Different laboratories may use different assays, units, and cut points. The most common mistake is to compare an activity result with a mass result or to use an internet cutoff that does not match the patient’s report.
Many current U.S. activity reports use a simple cardiovascular risk interpretation:
| Result type | Common units | Typical interpretation |
|---|---|---|
| Lp-PLA2 activity below 225 | nmol/min/mL | Often reported as reduced risk from this marker |
| Lp-PLA2 activity 225 or higher | nmol/min/mL | Often reported as increased risk from this marker |
| Lp-PLA2 mass | ng/mL | Uses different cutoffs; do not compare directly with activity values |
Some specialty labs use different activity thresholds, and some older mass-based interpretations use categories such as lower, borderline, or higher risk. Because of this variation, the lab’s own reference interval carries more weight than a general range.
Low or normal Lp-PLA2
A low or normal Lp-PLA2 result is generally reassuring for this specific marker. It suggests that Lp-PLA2-related vascular inflammation is not elevated by that assay at that time.
A normal result does not prove that the arteries are free of plaque. A person can still have high LDL cholesterol, high blood pressure, diabetes, high lipoprotein(a), coronary calcium, or plaque on imaging. A normal Lp-PLA2 should not be used to ignore major risk factors.
Borderline or mildly elevated Lp-PLA2
A borderline or mildly elevated result usually calls for context. For example, an Lp-PLA2 activity just above the lab cutoff in a young nonsmoker with excellent ApoB, normal blood pressure, and no family history has a different meaning than the same result in a person with diabetes, high blood pressure, and a family history of early heart attack.
When Lp-PLA2 is only mildly elevated, clinicians often look for patterns rather than react to the number alone. Helpful questions include:
- Is LDL cholesterol above the person’s risk-based target?
- Is ApoB high, suggesting many atherogenic particles?
- Are triglycerides high or HDL cholesterol low?
- Is blood pressure consistently elevated?
- Is there diabetes, insulin resistance, or chronic kidney disease?
- Is there a history of smoking?
- Is coronary artery calcium present?
- Is there carotid plaque or prior stroke/TIA?
An ApoB test can be especially helpful because Lp-PLA2 often travels on LDL particles. ApoB estimates the number of atherogenic particles, not just the cholesterol mass inside them.
High Lp-PLA2
A clearly high Lp-PLA2 result suggests increased plaque-related inflammatory activity, especially when paired with other abnormal cardiovascular markers. It may strengthen the case for more intensive prevention, but it rarely provides the whole answer by itself.
High Lp-PLA2 does not identify which artery is affected. It cannot tell whether plaque is in the coronary arteries, carotid arteries, aorta, or leg arteries. It also cannot tell whether a plaque will rupture. It is a risk marker, not a map.
High Lp-PLA2, Stroke Risk, and Heart Risk
High Lp-PLA2 is most relevant to atherosclerotic cardiovascular disease, including coronary heart disease and some forms of ischemic stroke. Its strongest biological fit is plaque disease, especially plaque that forms from LDL retention, oxidation, immune-cell activity, and inflammatory lipid products.
In heart disease, Lp-PLA2 has been studied as a marker of coronary plaque activity. People with higher levels or activity often have a higher rate of cardiovascular events in observational studies. This association tends to weaken after adjusting for standard risk factors, but it does not disappear in every study. That is why Lp-PLA2 may add information in selected patients but is not usually treated as a primary screening test for everyone.
In stroke risk, Lp-PLA2 appears most connected to large-artery atherosclerotic stroke. That type of stroke happens when plaque in a large artery, such as the carotid artery or an intracranial artery, narrows the artery or contributes to clot formation. Lp-PLA2 is less directly related to stroke caused by atrial fibrillation, small-vessel disease, or non-atherosclerotic causes.
This distinction matters. A high Lp-PLA2 result should not lead someone to assume all stroke risks are plaque-related. Atrial fibrillation, uncontrolled blood pressure, diabetes, smoking, sleep apnea, kidney disease, clotting disorders, and carotid disease can all contribute to stroke risk in different ways.
How Lp-PLA2 differs from cholesterol markers
LDL cholesterol tells how much cholesterol is carried inside LDL particles. ApoB tells how many atherogenic particles are present. LDL particle number gives another particle-count estimate. Lp-PLA2 reflects enzyme activity tied to oxidized lipids and inflammatory cells.
These markers can point in the same direction, but they do not always match. A person may have moderate LDL cholesterol but high ApoB because they have many cholesterol-poor particles. Another person may have high LDL cholesterol but normal Lp-PLA2. In more complex cases, an advanced lipid panel may help clarify whether the main issue is particle burden, insulin resistance, inherited lipoprotein risk, inflammation, or a combination.
How Lp-PLA2 relates to oxidized LDL and plaque instability
Lp-PLA2 is closely tied to oxidized LDL biology. Oxidized LDL can activate immune cells and irritate the artery lining. Lp-PLA2 acts on oxidized phospholipids and can generate inflammatory lipid products that may worsen local artery-wall inflammation.
This is why Lp-PLA2 is often discussed with oxidized LDL testing, small dense LDL, and other markers of plaque biology. Still, none of these markers can replace clinical risk assessment or imaging when symptoms or high-risk findings are present.
Why a high result does not automatically mean treatment failure
A high Lp-PLA2 result does not mean a person’s current treatment is useless. It may mean the treatment plan needs to be reviewed. It may also reflect years of prior risk exposure, current LDL particle burden, smoking, diabetes, or untreated blood pressure.
Cardiovascular prevention works by lowering the drivers of plaque growth and rupture over time. A single marker can lag behind, vary by assay, or improve gradually. The trend matters, but outcomes matter more.
Who May Benefit From Lp-PLA2 Testing
Lp-PLA2 testing is most reasonable when the result could change the intensity of prevention or prompt a closer look at plaque-related risk. It is usually less helpful when a person is already clearly low risk or already clearly high risk based on established disease.
A clinician may consider Lp-PLA2 testing in people with:
- Borderline or intermediate estimated cardiovascular risk
- Strong family history of early heart attack or stroke
- High LDL cholesterol with unclear treatment intensity
- High ApoB, high LDL particle number, or discordant lipid results
- Metabolic syndrome, insulin resistance, or type 2 diabetes
- Known carotid plaque or coronary artery calcium
- Prior transient ischemic attack or ischemic stroke where atherosclerosis is suspected
- Persistently high inflammatory risk but unclear hs-CRP interpretation
- Smoking history plus abnormal cholesterol markers
- Multiple moderate risk factors that do not look dramatic individually
Lp-PLA2 is rarely the first test to order. Most people need the basics first: blood pressure, smoking status, diabetes screening, kidney function, standard cholesterol testing, and family history. A high LDL cholesterol result or high ApoB usually has clearer treatment implications than Lp-PLA2 alone.
The test may be less useful when treatment decisions are already obvious. For example, a person with prior heart attack, symptomatic coronary disease, ischemic stroke from atherosclerosis, or very high LDL cholesterol already needs aggressive risk reduction. In those cases, Lp-PLA2 may be used for additional information, but it should not delay proven treatment.
Preparation and timing
Fasting is usually not required for Lp-PLA2 activity testing. However, the blood draw may be scheduled fasting if it is bundled with triglycerides, fasting glucose, insulin, or other tests that are easier to interpret after an overnight fast.
The test can usually be done from serum or plasma. Some labs ask that the sample be processed promptly. Hemolyzed, clotted, or very turbid samples may be rejected because they can interfere with accurate measurement.
Repeat testing is not usually needed every few weeks. If the result is being monitored after a treatment change, a repeat interval of about 3 to 6 months is more realistic. That gives LDL-lowering therapy, smoking cessation, weight loss, blood pressure improvement, and glucose control time to affect the risk pattern.
How High Lp-PLA2 Is Usually Addressed
High Lp-PLA2 is usually addressed by lowering overall atherosclerotic risk, not by treating the number in isolation. The most important steps target the drivers of plaque inflammation: atherogenic particles, smoking, high blood pressure, diabetes, obesity, poor sleep, inactivity, and unhealthy dietary patterns.
Lower LDL particle burden
Because much of circulating Lp-PLA2 travels on LDL particles, reducing LDL particle burden often helps. Statins can reduce Lp-PLA2 mass and activity, and they also reduce heart attack and stroke risk in appropriate patients. Ezetimibe, PCSK9 inhibitors, bempedoic acid, and other lipid-lowering therapies may be considered depending on the person’s risk level, LDL response, tolerance, and treatment goals.
The target is usually based on overall risk, not the Lp-PLA2 value alone. A person with established cardiovascular disease usually needs a much lower LDL cholesterol target than a young person with no other risk factors. ApoB can help when LDL cholesterol and risk do not seem to match.
Lipoprotein(a), or Lp(a), deserves separate attention because it is inherited and can raise cardiovascular risk even when LDL cholesterol looks acceptable. Testing Lp(a) levels is often helpful in people with family history of early heart disease or stroke.
Improve insulin resistance and triglyceride-rich particle patterns
Insulin resistance can create a pattern of high triglycerides, low HDL cholesterol, small dense LDL, fatty liver, abdominal weight gain, and higher ApoB. This pattern can increase plaque risk even when LDL cholesterol is not strikingly high.
Improving insulin resistance often requires a combined plan: weight reduction when needed, regular physical activity, higher-fiber foods, fewer refined carbohydrates, better sleep, and treatment of diabetes or prediabetes when present. The metabolic syndrome blood test pattern can help show whether Lp-PLA2 is part of a wider cardiometabolic problem.
Triglycerides also matter because high levels often reflect remnant particles and insulin resistance. Very high triglycerides raise pancreatitis risk, while moderately high triglycerides can signal higher atherogenic remnant burden. When triglycerides stay elevated, clinicians often review alcohol intake, refined carbohydrate intake, thyroid function, diabetes control, medications, and genetic factors.
Stop smoking and lower oxidative stress exposures
Smoking directly injures the artery lining, promotes oxidation, increases clotting tendency, and accelerates plaque disease. For a person with high Lp-PLA2, smoking cessation is one of the highest-impact interventions.
Secondhand smoke, untreated sleep apnea, chronic gum disease, uncontrolled blood pressure, and poorly controlled diabetes can also add inflammatory stress to blood vessels. Addressing these factors can reduce overall vascular risk even if the exact Lp-PLA2 response varies.
Use food patterns that lower plaque risk
A heart-protective diet does not need to be extreme. The strongest patterns emphasize whole foods and reduce the combination of excess saturated fat, refined starches, added sugars, and ultra-processed foods.
Useful dietary priorities include:
- Replace butter, high-fat processed meats, and many fried foods with unsaturated fats such as olive oil, nuts, seeds, and avocado.
- Eat soluble fiber from oats, barley, beans, lentils, fruit, and psyllium when appropriate.
- Choose fish, legumes, low-fat dairy, poultry, or minimally processed protein sources more often than processed meats.
- Keep refined carbohydrates and added sugars low, especially when triglycerides or glucose are high.
- Limit alcohol if triglycerides, liver enzymes, blood pressure, or weight are concerns.
- Use sodium reduction when blood pressure is elevated.
Omega-3 intake may help triglycerides and overall cardiometabolic health, but it should not be viewed as a direct Lp-PLA2 treatment. Prescription omega-3 therapy is a separate medical decision for selected patients with elevated triglycerides and cardiovascular risk.
Exercise consistently
Regular physical activity improves blood pressure, insulin sensitivity, HDL function, triglycerides, inflammation, and weight regulation. A common target is at least 150 minutes per week of moderate aerobic activity, plus two sessions of resistance training. People who are inactive can start with shorter walks and build gradually.
Exercise should be matched to symptoms and medical history. Chest pressure, unusual shortness of breath, fainting, or exercise-triggered pain deserves medical evaluation before pushing harder.
Follow-Up Tests, Common Mistakes, and Urgent Symptoms
A high Lp-PLA2 result should lead to a structured cardiovascular risk review. The follow-up depends on the person’s age, symptoms, risk factors, medical history, and other lab results.
Common follow-up tests and checks may include:
| Follow-up area | Why it helps |
|---|---|
| Lipid panel, ApoB, non-HDL cholesterol | Shows atherogenic cholesterol and particle burden |
| Lp(a) | Identifies inherited lipoprotein risk that may explain family history |
| HbA1c, fasting glucose, fasting insulin when appropriate | Looks for diabetes, prediabetes, or insulin resistance patterns |
| Blood pressure review | Hypertension is one of the strongest stroke and heart risk factors |
| Kidney function and urine albumin | Kidney disease increases vascular risk and affects treatment choices |
| hs-CRP when appropriate | Adds information about systemic inflammatory risk |
| Coronary artery calcium or carotid imaging in selected people | Can show whether plaque is already present |
Imaging should not be automatic for every high Lp-PLA2 result. It is most useful when the result could change treatment intensity, when risk is uncertain, or when symptoms or family history raise concern.
Common mistakes when interpreting Lp-PLA2
The most common mistake is treating Lp-PLA2 as a stand-alone diagnosis. It is not. A high value does not prove blocked arteries, and a low value does not prove clean arteries.
Another mistake is comparing numbers across different assay types. Activity and mass are different measurements. Even two activity tests may use different cutoffs if performed by different labs.
A third mistake is focusing only on inflammation while ignoring LDL particle burden. Plaque inflammation is usually driven by a long-term supply of atherogenic particles entering the artery wall. If ApoB, LDL cholesterol, non-HDL cholesterol, or lipoprotein(a) is high, those drivers need attention.
A fourth mistake is using Lp-PLA2 to postpone proven therapy. If a person clearly qualifies for LDL-lowering medication, blood pressure treatment, diabetes treatment, or smoking cessation support, waiting for repeated specialty markers can waste time.
When symptoms need urgent care
Lp-PLA2 is not an emergency test. Symptoms decide urgency.
Seek emergency medical care right away for:
- Chest pressure, squeezing, heaviness, or pain that lasts more than a few minutes
- Pain spreading to the arm, jaw, back, neck, or stomach
- Sudden shortness of breath, sweating, nausea, or fainting with chest discomfort
- Sudden facial droop, arm weakness, speech trouble, confusion, or vision loss
- Sudden severe headache unlike usual headaches
- New one-sided numbness, weakness, trouble walking, or loss of balance
These symptoms can represent heart attack, stroke, or another urgent condition even if prior blood tests were normal.
How to think about repeat testing
Repeat Lp-PLA2 testing can be reasonable after major changes in treatment or risk factors. A repeat test after 3 to 6 months may show whether the marker is moving in the desired direction. It should be checked alongside the markers that guide treatment more directly, such as LDL cholesterol, ApoB, non-HDL cholesterol, blood pressure, HbA1c, kidney function, and smoking status.
A falling Lp-PLA2 result can be encouraging, but it should not lead to stopping therapy if the person still has high cardiovascular risk. A persistently high result should prompt a careful search for ongoing drivers, such as untreated LDL particle burden, smoking, diabetes, chronic kidney disease, medication nonadherence, or unrecognized plaque.
Lp-PLA2 can add a useful layer to cardiovascular risk assessment, especially when standard markers do not tell the whole story. Its best role is as a signal to take plaque biology seriously and to strengthen prevention based on the full risk profile.
References
- Lipoprotein-associated phospholipase A2 (Lp-PLA2): a key hub linking lipid metabolism and immune inflammation 2026 (Review)
- The Value of Lp-PLA2 as a Biomarker for the Diagnosis of Plaque Stability in Atherosclerosis: A Meta-Analysis 2025 (Meta-Analysis)
- Effect of Statin Treatment on Lipoprotein-Associated Phospholipase A2 Mass and Activity: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials 2025 (Systematic Review)
- Causal Effect of Lipoprotein-Associated Phospholipase A2 Activity on Ischemic Stroke: A Mendelian Randomization Study 2024 (Mendelian Randomization Study)
- 123283: Lipoprotein-associated Phospholipase A2 Activity | Labcorp 2026 (Lab Test Directory)
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines 2019 (Guideline)
Disclaimer
Lp-PLA2 results should be interpreted by a qualified healthcare professional in the context of symptoms, medical history, medications, and other cardiovascular risk markers. A high Lp-PLA2 result does not diagnose a heart attack, stroke, or blocked artery, and a normal result does not rule out cardiovascular disease. Seek urgent medical care for chest pain, stroke symptoms, fainting, severe shortness of breath, or sudden neurological changes.
